Osiris Therapeutics, Inc. researches, develops, manufactures, markets, and distributes regenerative medicine products in the United States. Its products include Grafix and Stravix for treating chronic wounds of diabetic foot ulcers, venous leg ulcers, pressure ulcers, arterial ulcers, and severe burns, as well as surgical and trauma wounds; BIO4 for bone repair and regeneration in spine, trauma, extremity, cranial, and foot and ankle surgeries; and Cartiform for treating articular cartilage lesions in the knee and other joints. The company also develops and markets Menvivo for the repair of meniscus; and TruSkin for treating chronic wounds. It markets and distributes its products directly to physicians, hospitals, and other healthcare providers, as well as through agents and distributors. Osiris Therapeutics, Inc. was founded in 1992 and is headquartered in Columbia, Maryland.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolOTCMKTS:OSIR
CUSIP68827R10
Phone443-545-1800
Debt
Debt-to-Equity RatioN/A
Current Ratio1.97
Quick Ratio1.68
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$118.51 million
Price / Sales2.80
Cash FlowN/A
Price / CashN/A
Book Value$1.20 per share
Price / Book8.00
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees350
Outstanding Shares34,530,000
Osiris Therapeutics (OTCMKTS:OSIR) Frequently Asked Questions
What is Osiris Therapeutics' stock symbol?
Osiris Therapeutics trades on the OTCMKTS under the ticker symbol "OSIR."
Who are some of Osiris Therapeutics' key competitors?
Some companies that are related to Osiris Therapeutics include Cellectis (CLLS), Iovance Biotherapeutics (IOVA), Adaptimmune Therapeutics (ADAP), DBV Technologies (DBVT), BAVARIAN NORDIC/S (BVNRY), Solid Biosciences (SLDB), Coherus Biosciences (CHRS), La Jolla Pharmaceutical (LJPC), Heska (HSKA), Voyager Therapeutics (VYGR), Fate Therapeutics (FATE), Novavax (NVAX), BioCryst Pharmaceuticals (BCRX), Mesoblast (MESO) and CASI Pharmaceuticals (CASI).
Who are Osiris Therapeutics' key executives?
Osiris Therapeutics' management team includes the folowing people:
- Mr. Jason Keefer, Interim Pres & CEO (Age 46)
- Dr. Alla N. Danilkovitch, Chief Scientific Officer (Age 54)
- Mr. Joel David Rogers, Interim Chief Financial Officer (Age 56)
- Mr. Edward Yip, Chief Legal Officer & Corp. Sec.
- Mr. Laine Dyess, VP of Sales
Has Osiris Therapeutics been receiving favorable news coverage?
Media stories about OSIR stock have trended somewhat negative this week, according to Accern. The research group rates the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Osiris Therapeutics earned a news sentiment score of -0.20 on Accern's scale. They also assigned news articles about the biotechnology company an impact score of 45.91 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
How do I buy shares of Osiris Therapeutics?
Shares of OSIR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Osiris Therapeutics' stock price today?
One share of OSIR stock can currently be purchased for approximately $9.60.
How big of a company is Osiris Therapeutics?
Osiris Therapeutics has a market capitalization of $320.74 million and generates $118.51 million in revenue each year. Osiris Therapeutics employs 350 workers across the globe.
How can I contact Osiris Therapeutics?
Osiris Therapeutics' mailing address is 7015 ALBERT EINSTEIN DRIVE, COLUMBIA MD, 21046. The biotechnology company can be reached via phone at 443-545-1800 or via email at [email protected]
MarketBeat Community Rating for Osiris Therapeutics (OSIR)
MarketBeat's community ratings are surveys of what our community members think about Osiris Therapeutics and other stocks. Vote "Outperform" if you believe OSIR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OSIR will underperform the S&P 500 over the long term. You may vote once every thirty days.
